secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2022-04-25T23:59:59+00:00
Accession:  0001104659-22-049634
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q1 revenue $4.1M (+43% YoY); US HF revenue up 133% to $2.9M
----------------------------------------------------------------

- Net loss $10.0M ($0.49 per share) vs $8.6M loss ($23.92 per share) in Q1 2021; weighted avg shares 20.45M.
- U.S. active implanting centers grew to 56 from 19; sales territories expanded to 17 from 6 year-over-year.
- Cash $131.2M at Mar 31, 2022; full-year 2022 revenue guidance $20-23M; Q2 expected $4.5-5M.
- Received FDA approval for new tablet-form factor programmer in April 2022.
- Gross margin improved to 77% from 70%; R&D $2.3M (+29%), SG&A $10.8M (+142%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465922049634/0001104659-22-049634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465922049634/tm2213448d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-049634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer